^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 negative

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    1d
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. (clinicaltrials.gov)
    P3, N=752, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    HER-2 negative • HER-2 expression • CLDN18.2 positive • CLDN1 positive
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • tecotabart vedotin (LM-302)
    1d
    Abemacilib-Related Radiation Recall Dermatitis Post Breast Reconstruction: A Case Report and Literature Review. (PubMed, Thorac Cancer)
    Adjuvant radiotherapy and intensive endocrine therapy (endocrine therapy and abemaciclib) were administered postoperatively...This flap necrosis was suggestive of RRD. This report details the clinical course, management strategies, and a review of relevant literature, aiming to provide valuable insights for clinicians in handling similar cases and enhance awareness of potential risks associated with this treatment combination.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Verzenio (abemaciclib)
    1d
    A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Jul 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Datroway (datopotamab deruxtecan-dlnk)
    2d
    Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Apr 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    paclitaxel • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide
    2d
    Exercise, Fitness and Tumor Profiling in Breast Cancer Patients (clinicaltrials.gov)
    P=N/A, N=42, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative
    2d
    p-AKT p-S6: PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study (clinicaltrials.gov)
    P=N/A, N=70, Not yet recruiting, Assiut University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    2d
    Predicting progression-free survival in hormone-receptor positive (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach. (PubMed, Breast)
    This study supports the clinical applicability ML models using baseline clinicopathological variables for individualized risk stratification in HR+/HER2- MBC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    2d
    Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinoma. (PubMed, Proc Natl Acad Sci U S A)
    Notably, the P subtype was linked to poor prognosis, even in patients treated with endocrine therapy alone, while the NSE subtype was associated with favorable outcomes. Our findings uncover spatial and cellular heterogeneity in ILC that is not captured by existing classification approaches, offering a refined framework for risk stratification and therapeutic targeting based on tumor microenvironment architecture.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    2d
    Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-Null to HER2-low, including HER2-ultralow status. (PubMed, Virchows Arch)
    Despite some significantly different clinicopathological features, there is no solid evidence to support HER2-ultralow, HER2-low and HER2-null cancers as individual TNBC clinical-molecular entities. Particularly, assigning TNBC samples to the HER2-null, -ultralow and -low categories did not bring any additional prognostic value.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD163 (CD163 Molecule)
    |
    PD-L1 expression • HER-2 amplification • HER-2 negative
    2d
    Dalpiciclib in HR+/HER2- ABC (clinicaltrials.gov)
    P=N/A, N=103, Recruiting, RenJi Hospital | Trial primary completion date: Dec 2025 --> Jan 2027
    Trial primary completion date • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    AiRuiKang (dalpiciclib)